Among patients with PAH, macitentan was associated with a decreased risk for all-cause and PAH-related hospitalization.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged, metastatic NSCLC, according to researchers.